Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    FDA Requests Boxed Warnings on Conventional Antipsychotic Drugs - (DGNews)
    Pramlintide-Related Improvements in Diabetes Benefit Patients' Psyche: Presented at ADA - (DGDispatch)
    Health Canada Approves New Treatment for Bipolar Mania - (DGNews)
    Report Confirms Increased Risk of Smoking, Substance Abuse in Bipolar Adolescents - (DGNews)
    Short-Term Antipsychotics in Older Adults With Dementia Associated With Serious Adverse Events - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder
      Delirium Update
      The Pharmacist's Role in Breaking the Cycle of PMDD
      Understanding Autism: The Role of the Pharmacist in the Management of Autism

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Childhood Autism in a 13 Year Old Boy with Oculocutaneous Albinism: A Case Report
        Unexpected Depletion in Plasma Choline and Phosphatidylcholine Concentrations in a Pregnant Woman with Bipolar Affective Disorder Being Treated with Lithuim, Haloperidol and Benztropine: A Case Report
        Recognizing Thyrotoxicosis in a Patient with Bipolar Mania: A Case Report

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Acute Treatment with Atomoxetine Equally Effective in Children and Adolescents: Presented at AACAP

        By Paula Moyer

        TORONTO, CANADA -- November 14, 2005 -- Acute treatment of attention deficit hyperactivity disorder (ADHD) with atomoxetine (Strattera) is as effective and well tolerated in children as it is in adolescents, according to a study presented at the joint annual meeting of the American and Canadian Academies of Child and Adolescent Psychiatry (AACAP/CACAP).

        "Atomoxetine is efficacious for the acute treatment of ADHD in children and adolescents," said principal investigator Timothy E. Wilens, MD. "Robustness and time to response of ADHD symptoms were similar between age groups."

        Dr. Wilens is the director of substance abuse services in pediatric pharmacology at Massachusetts General Hospital, and Professor of Psychiatry, Harvard Medical School Boston, Massachusetts, United States.

        The researchers conducted the study to resolve the controversy regarding the tolerability and response to certain ADHD medications across the life span. They conducted a meta-analysis of six double-blind, placebo-controlled studies in which patients received atomoxetine or placebo once or twice daily for 6 to 9 weeks.

        The analysis involved 851 patients <12 years old and 176 who were 12 years old or older. The efficacy measures included the ADHD Rating Scale (ADHD RS), the Clinical Global Impression-Severity (CGI-S) scores, the Conners Parent Rating Scale-ADHD (CPRS-ADHD), response rates, and times to response. Response was defined as a decrease of at least 25% on the ADHD RS score.

        Scores on the CPRS-ADHD decreased an average of 8.41 points in treated children and 8.31 points in treated adolescents, compared to an average decrease of 2.45 points and 1.62 points in the respectively placebo groups.

        Similarly, scores on the ADHD RS, which were lower at baseline in adolescents, decreased similarly in both age groups compared to placebo (P < .001). CGI-S scores also decreased an average of 1.4 points in each group.

        Response rates were 59.3% in treated children and 61.1% in treated adolescents, compared to 30.9% and 35.4% of placebo subjects, respectively. The time to response was approximately 5 days for treated subjects in each age group.

        The investigators found no significant differences between the age groups regarding overall rates of adverse events, vital signs, laboratory values, changes in height or weight, and electrocardiogram.

        Although the rates of headache were similar between the groups (20.9% in children and 20.8% in adolescents), children were more likely to report treatment-emergent headaches.

        "The analysis of adverse events by age did not suggest clinically meaningful differences in tolerability between adolescents and children," Dr. Wilens said.

        The study was funded by Eli Lilly and Company, which manufactures Strattera.


        [Presentation title: Acute Effects of Atomoxetine in Children versus Adolescents. Abstract C45]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send